BUZZ- Barclays raises <a href="https://laohu8.com/S/PHAT">Phathom Pharmaceuticals</a> to 'overweight'; shares rise** Gastrointestinal (GI) diseases-focused biopharma Phathom Pharmaceuticals PHAT.O shares rise 2% to $11 premarket
** Barclays upgrades stock to "overweight" from "equal-weight"
** Brokerage raises target price to $18 from $16, which represents 66.8% upside from the stock's last close
** "We think the combination of a strengthened balance sheet, strong guidance and focused commercial strategy suggests the stock at ~$11 is dislocated from the fundamentals" - Barclays
** Brokerage notes that more targeted GI approach appears positioned to drive better adoption
** As of last close, stock has fallen 34.9% YTD
(Reporting by Ragini Mathur in Bengaluru)
((Ragini.Mathur@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.